Personalised Treatment With Olaparib For Advanced Prostate Cancer 

Monday Lunch Livestream

With Associate Professor Shahneen Sandhu

30 August 2021

Hear a presentation on the recently approved drug, Olaparib, an oral medication used to treat men with metastatic castration-resistant prostate cancer (mCRPC) and underlying DNA repair issues. 

Alterations in DNA repair genes such as BRCA1/2 occur in about 20 percent of men with metastatic prostate cancer. Recent Phase III trials have shown the positive effects of the drug, Olaparib, and based on this data the drug has been approved for use by the US Food and Drug Administration (FDA), and the Therapeutic Goods Administration Australia (TGA).

In this presentation Associate Professor Shahneen Sandu reviews the DNA gene alterations in advanced prostate cancer that can be targeted with the drug, and discuss how these genetic alterations can be identified. She will also highlight the implications and safety of the drug, with opportunity for discussion.

Associate Professor Shahneen Sandhu 

Associate Professor Shahneen Sandu is a medical oncologist and an early-career researcher with a full time appointment in the uro-oncology and melanoma units at the Peter MacCallum Centre. Over the course of her research career, she has made important contributions to cancer research, particularly in the development and application of clinical biomarkers and novel therapies for prostate cancer. She continues to undertake clinical and translational research in melanoma and prostate cancer with a focus on using imaging and circulating biomarkers to molecularly stratify treatment.